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Abstract 
Migration from areas with a high incidence of 
rheumatic heart disease has led to an increase in 
pregnancy complicated by rheumatic heart 
disease in high-income countries. We present a 
case of rheumatic heart disease diagnosed in a 
33-year-old G2P0010 French-speaking 
Congolese woman at 32 weeks gestation. She 
was initially hospitalized with respiratory syncytial 
virus (RSV) bronchiolitis at 24 weeks gestation 
and established care in our clinic. Mitral valve 
stenosis was identified at 32 weeks gestation 
after she presented with severe edema and was 
hospitalized for acute on chronic heart failure 
complicated by urosepsis and cellulitis. She was 
managed in the cardiovascular intensive care unit 
with a subsequent emergent cesarean delivery at 
33 weeks gestation for nonreassuring fetal status. 
Postoperatively, pulmonary artery pressures 
were 40 mm Hg and left ventricular ejection 
fraction was 35%. Her condition stabilized and 
she was discharged home with outpatient 
cardiology management on postoperative day 10 
with baby in the NICU. This case illustrates the 
importance of a high threshold of suspicion for 
women at risk for complications of heart disease 
in pregnancy. A triad of cardiovascular risk 
screening, patient education and multidisciplinary 
team planning with maternal-fetal medicine, 
cardiology, and anesthesiology has been shown 
to optimize outcomes in women with known 
cardiovascular disease. 
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Introduction 
In the United States, 26.5% of 
pregnancy-related deaths are due to 
cardiovascular disease, making it the 
leading cause of death in pregnancy 
during the postpartum period.1 As the 
incidence of pregnancy in women with 
congenital and acquired heart disease 
continues to rise, it is imperative to have 
a high threshold of suspicion for women 
at risk for maternal heart disease and 
pregnancy-related mortality and 
morbidity.2 Furthermore, there exists a 
disparity in pregnancy outcomes 
complicated by cardiovascular disease 
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among lower income women. Barriers 
include lack of pre-pregnancy 
cardiovascular disease assessment, 
failure to identify cardiovascular disease 
risk factors during prenatal care, gaps in 
high-risk intrapartum care and delay in 
recognizing cardiovascular disease 
symptoms in the postpartum period.1 
In low-income countries, rheumatic heart 
disease accounts for 90% of all 
cardiovascular disease in pregnant 
women.3 Increased migration from areas 
with high incidence of rheumatic heart 
disease has led to an increase in 
pregnancy complicated by rheumatic 
heart disease in high-income countries.4 
We present a case of rheumatic heart 
disease diagnosed in the third trimester 
of pregnancy at the University of Iowa 
Hospital and Clinics.  
Case History 
A 33-year-old G2P0010 Congolese 
woman at 24 weeks gestation with type 2 
diabetes mellitus and uterine fibroids was 
transferred from her local intensive care 
unit 1.5 hours away to our medical 
intensive care unit for hypoxemic 
respiratory failure secondary to 
respiratory syncytial virus (RSV) 
bronchiolitis. She was managed by 
internal medicine with oral prednisone 
and bronchodilators and received 
antibiotics for a urinary tract infection. 
After discharge, her prenatal care was 
transferred to our high-risk obstetrics 
clinic at 29 weeks gestation.  
At 32 weeks gestation, she presented 
with bilateral lower extremity swelling and 
tachycardia. She reported 2 weeks of 
worsening edema that became painful 
and weeping. Given prior outside 
echocardiogram showing mitral valve 
stenosis, she was admitted for acute or 
chronic heart failure and concern for 
cellulitis. Transthoracic echocardiogram 
revealed 45% - 50% ejection fraction, 
mildly enlarged right atrial chamber, right 
ventricle, and left atrium. Cardiology 
identified mitral valve stenosis and 
moderate tricuspid regurgitation 
consistent with rheumatic heart disease 
with elevated right-sided pressures. The 
mitral valve mean gradient was 7 mm Hg 
(normal <5 mm Hg). She was medically 
managed in the cardiac intensive care 
unit and received antibiotics for cellulitis 
and E.coli urosepsis. On hospital day 7, 
fetal heart rate monitoring became 
nonreassuring and she underwent an 
emergent cesarean delivery at 33 weeks 
gestation.  
The infant was delivered at 2.73 kg with 
Apgar scores of 5 at one minute and 9 at 
five minutes. Postoperatively, she 
remained intubated on vasopressors with 
pulmonary artery pressures at 40 mm Hg 
and LVEF 35%. On postoperative day 3 
her ejection fraction returned to 45%. 
She required 2 units of blood for 
symptomatic anemia and was 
discharged in stable condition on 
postoperative day 10. She denied any 
knowledge of rheumatic fever as a child 
or history of heart disease. Her care was 
complicated by a French Lingala 
language barrier requiring phone 
interpretation services.  
Discussion  
The incidence of rheumatic fever in high-
income countries has decreased 
substantially due to rapid diagnosis and 
treatment of streptococcal pharyngitis.4 
Rheumatic heart disease may occur 
following acute rheumatic fever where an 
immunological response leads to 
antibodies formed against M proteins of 
the bacteria. The antibodies cross react 
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with glycoprotein antigens in the heart, 
joints, and other tissues. These 
antibodies lead to inflammation of the 
heart resulting in progressive fibrosis of 
the mitral valve. The most common 
cardiac sequelae of rheumatic heart 
disease is mitral stenosis.  
In low-income countries, rheumatic heart 
disease comprises 50-88% of heart 
disease during pregnancy.5 This is 
highest among populations in Sub-
Saharan Africa occurring in 
approximately 13 per 1,000,000 
pregnancies.6 Mitral stenosis is usually of 
rheumatic origin and severity of mitral 
stenosis is correlated with increase 
maternal risk for congestive heart failure, 
pulmonary edema, arrhythmia, and 
maternal death. Stenotic valves also limit 
increase in stroke volume reducing 
uteroplacental perfusion and leading to 
intrauterine growth restriction, preterm 
delivery, and stillbirth. Physiologic 
changes to the cardiovascular system in 
pregnancy result in increased preload on 
the heart due to increased blood volume 
and cardiac output. In the postpartum 
period, cardiac output remains elevated 
due to decreased caval compression, 
autotransfusion from the uterus, and 
resorption of extracellular fluid into the 
intravascular compartment. These 
hemodynamic changes place women at 
greatest risk and necessitates increased 
surveillance during pregnancy and the 
puerperium.3  
It is important to recognize the disparity 
that exists in cardiovascular outcomes in 
pregnancy among lower-income women 
given our patient has Congolese 
heritage, primarily spoke French Lingala, 
and had a significant travel barrier to our 
tertiary care center. U.S. data shows 
non-Hispanic black women have a 3.4 
increased risk of mortality from 
cardiovascular pregnancy 
complications.7 This disparity can be 
partially attributed to structural and 
systemic barriers that prevent the 
provision of health care. Furthermore, 
physician implicit and explicit bias can 
play a role in missed diagnosis. In our 
case, the language barrier played a 
significant role in healthcare provision.  
The Modified World Health Organization 
Pregnancy Risk Classification for 
Women with Pre-existing Cardiovascular 
Disease classifies women with moderate 
mitral stenosis as Class III with a 
significantly increased risk of maternal 
mortality or severe morbidity. There is a 
20-27% maternal cardiac event rate, and 
the WHO recommends follow up with 
cardiology every 1-2 months. Women 
with severe mitral stenosis are classified 
as WHO Class IV with an extremely high 
risk of maternal mortality and severe 
morbidity. The maternal cardiac event 
rate is >27% and pregnancy is 
contraindicated.1 Our patient qualified as 
WHO Class III risk and due to delay in 
diagnosis was unable to be established 
with cardiology per WHO 
recommendations.  
Prior to conception, women with 
congestive heart failure, NYHA Class > II 
and moderate or severe mitral stenosis 
defined as a mitral valve area < 1.5 cm2 
are candidates for percutaneous balloon 
mitral valvuloplasty. Asymptomatic 
women with moderate to severe mitral 
stenosis should be evaluated for exercise 
capacity and exercise induced 
pulmonary hypertension. Women with 
excellent exercise capacity and normal 
pulmonary artery pressure may not need 
surgical intervention. Barriers to timely 
antenatal care or urgent percutaneous 
valvuloplasty should be considered when 
evaluating an asymptomatic woman with 
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moderate to severe mitral stenosis for 
percutaneous intervention prior to 
pregnancy. However, the 2014 American 
Heart Association / American College of 
Cardiology recommends preconception 
percutaneous mitral balloon 
commissurotomy for asymptomatic 
patients with a mitral valve area < 1.5 
cm2.8 
Women with mitral stenosis in pregnancy 
can be managed medically with beta 
blockers and diuretics with monthly or 
bimonthly follow up for moderate to 
severe mitral stenosis per the 2011 
European Society of Cardiology 
guidelines.9 Percutaneous balloon mitral 
valvuloplasty is an established treatment 
option in pregnancy with class III and IV 
heart failure refractory to medical 
management.10 Surgical intervention is 
recommended after 20 weeks gestation, 
but prior to late in the third trimester as 
the gravid uterus can interfere with 
femoral access. Time for intervention 
involves balancing risk of emergent 
delivery during the procedure as 
neonatal outcome improves with 
advanced gestational age versus 
increased maternal decompensation 
from severe mitral stenosis leading to 
emergency delivery compromising both 
maternal and fetal survival.  
In conclusion, it is important to recognize 
the social determinants of health in 
cardiovascular disease outcomes during 
pregnancy and have a high threshold of 
suspicion for women at risk for 
complications of heart disease in 
pregnancy. A triad of cardiovascular risk 
screening, patient education and 
multidisciplinary team planning with 
maternal fetal medicine, cardiology, and 
anesthesiology has been shown to 
optimize outcomes in women with known 
cardiovascular disease.11  
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